Results 71 - 80 of 218 : Previous 4 5 6 7 8 9 10 11 12 Next
The drugmaker's Copaxone for multiple sclerosis fails to show a benefit at double strength.
Yesterday's market is today's road map.
As the FDA Generics Office Turns
The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
A couple of extra billion dollars is nice.
Change a Label, Change the Game
Teva's Parkinson's drug does more than treat symptoms.
Find great values and fuel your financial future.
Mylan Takes Generic Aim at Teva
Mylan licenses a generic version of Teva's MS drug, Copaxone.
The millionaire's portfolio may surprise you.
Maybe what glitters really is gold.
Taking a Walk With a 10-Bagger
Acorda gets it done with phase 3 trial data on a new MS drug.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK